Does Rallies show 13F holders for BIIB?

Yes. Rallies tracks hedge fund and 13F ownership data for BIIB, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BIIB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BIIB. It does not provide personalized investment advice.

BIIB (Biogen) Stock Analysis - Hedge Fund Holdings

Biogen (BIIB) is a publicly traded Healthcare sector company. As of May 20, 2026, BIIB trades at $187.75 with a market cap of $28.33B and a P/E ratio of 20.20. BIIB moved -1.35% today. Year to date, BIIB is +7.16%; over the trailing twelve months it is +47.22%. Its 52-week range spans $110.04 to $205.97. Analyst consensus is buy with an average price target of $218.76. Rallies surfaces BIIB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BIIB stock?

Hedge funds tracked by Rallies that own BIIB include Pinebridge Investments, Panagora Asset, Orbimed Advisors, Glenview Capital, and Bridgewater Associates. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Biogen.

BIIB Key Metrics

Key financial metrics for BIIB
Metric	Value
Price	$187.75
Market Cap	$28.33B
P/E Ratio	20.20
EPS	$9.35
Dividend Yield	0.00%
52-Week High	$205.97
52-Week Low	$110.04
Volume	668.76K
Avg Volume	0
Revenue (TTM)	$9.94B
Net Income	$1.37B
Gross Margin	75.49%

Top Hedge Funds Holding BIIB

Pinebridge Investments holds 249.80K shares of BIIB, changed +430.54% as of Dec 31, 2024.
Panagora Asset holds 142.06K shares of BIIB, changed +4335.37% as of Mar 31, 2026.
Orbimed Advisors holds 61.60K shares of BIIB, changed -87.90% as of Mar 31, 2026.
Glenview Capital holds 57.02K shares of BIIB, changed -80.38% as of Mar 31, 2026.
Bridgewater Associates holds 39.98K shares of BIIB, changed -42.91% as of Sep 30, 2025.

Latest BIIB News

Biogen Acquires Apellis for $5.3B and Advances Tau Drug, Shares Jump 10% — May 15, 2026
Biogen drops after Phase 2 CELIA diranersen data, despite plan for Phase 3 — May 14, 2026
Biogen Completes $41-Per-Share Apellis Acquisition While Alzheimer’s Drug Misses Primary Endpoint — May 14, 2026
Biogen’s Apellis Acquisition Spurs SmallCap 600 Removal on May 14 — May 7, 2026
Bright Horizons, Remitly Join S&P SmallCap 600 as Apellis and Tri Pointe Exit — May 7, 2026

Recent BIIB Insider Trades

Murphy Nicole bought 3 (~$585.105) on Feb 12, 2026.
Singhal Priya sold 2.66K (~$531.55K) on Feb 9, 2026.
Singhal Priya sold 748 (~$134.12K) on Feb 2, 2026.

BIIB Analyst Consensus

26 analysts cover BIIB: 0 strong buy, 15 buy, 10 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $218.76.

Common questions about BIIB

Who owns BIIB stock?: Hedge funds tracked by Rallies that own BIIB include Pinebridge Investments, Panagora Asset, Orbimed Advisors, Glenview Capital, and Bridgewater Associates. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Biogen.
Does Rallies show 13F holders for BIIB?: Yes. Rallies tracks hedge fund and 13F ownership data for BIIB, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BIIB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BIIB. It does not provide personalized investment advice.